

## ORGANISATION

Hugues de Thé, Chaire oncologie cellulaire et moléculaire  
Alain Fischer, Chaire médecine expérimentale

# Cancer and immunity

COLLOQUE — 19-20 mai 2022

Amphithéâtre Marguerite de Navarre



## Jeudi 19 mai 2022

09h00 Introduction

Thomas RÖMER, Administrator of Collège de France,  
Hugues de THÉ, Alain FISCHER

### Tumor immunogenicity and T cell responses

09h15 Philippe BOUSSO, Institut Pasteur, Paris

Mechanisms of tumor immunosurveillance and immunotherapy analyzed at the single cell level

09h50 Ido AMIT, Weizmann Institute, Rehovot

The power of ONE :  
Immunology in age of single cell genomics

10h25 Miriam MERAD, Mount Sinai Medical School, New York

Myeloid cell control of antitumor immunity

11h00 Break

11h20 Emmanuel DONNADIEU, Institut Cochin, Paris

Imaging of T cell success and failure in human tumors

11h55 Hélène SALMON, Institut Curie, Paris,

Mount Sinai medical School, New York  
Contribution of the stromal cell compartment to tumor immunity

12h30 Break

14h00 Jérôme GALON, INSERM, Sorbonne Université, Paris

The immune contexture in the era of cancer immunotherapy

### Metabolism and pathogenesis

14h35 Craig B. THOMPSON, MSKCC, New York

The role of cancer metabolism in creating an immunosuppressive tumor microenvironment

15h10 Riccardo DALLA FAVERA, Columbia University, New York

Mechanisms of B cell lymphomagenesis

15h45 Break

16h05 Vishva M DIXIT, Genentech, San Francisco

Why so many ways to die ?  
The Non canonical inflammasome pathway

16h40 Éric VIVIER, CIML, Innate Pharma, Marseille

Harnessing innate immunity in cancer therapy

## Vendredi 20 mai 2022

### Tumor Checkpoint inhibitors

09h00 Ton SCHUMACHER, NCI, Amsterdam

Immunological response of human cancers to PD-1 blockade

09h35 Tasuku HONJO, Kyoto University (Video)

A new dimension of PD-1 blockade therapy against cancer

10h10 Caroline ROBERT, Institut Gustave Roussy, Villejuif

Translational control of cancer immunity

10h45 Break

11h05 Laurence ZITVOGEL, Institut Gustave Roussy, Villejuif

The impact of the intestinal microbiota in tumor immunosurveillance

11h40 Louis M STAUDT, NIH, Washington DC

Targeted therapy of immune-edited lymphomas

12h15 Break

### Cellular immunotherapy of cancer

14h00 Michel SADELAIN, MSKCC, New York

How CARs were built and how they work

14h35 Carl H JUNE, University of Pennsylvania, Philadelphia (Video)

CAR T cell therapies for cancer : progress and challenges

15h10 Sébastien AMIGORENA, Institut Curie, Paris

Heterochromatin and anti tumor immunity

15h45 Break

16h10 Sonia GUEDAN, IDIBAPS, Barcelona

CAR-T cell therapy for solid tumors

16h45 Martine PICCART, Institut Jules Bordet, ULB, Bruxelles

Implementation of innovative immunotherapy of cancer

17h30 Conclusions : Hugues de THÉ and Alain FISCHER

Avec le soutien de :

